Autoimmunity, inflammatory bowel disease and cancer

The goblet cell-derived mediator RELM-β drives spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis

Article metrics

Abstract

Intestinal goblet cells are potentially key players in controlling susceptibility to ulcerative colitis (UC). Although impaired mucin (Muc2) production by goblet cells increases microbial stimulation of the colonic mucosa, goblet cells secrete other mediators that may influence or promote UC development. Correspondingly, Muc2-deficient (−/−) mice develop spontaneous colitis, concurrent with the dramatic upregulation of the goblet cell mediator, resistin-like molecule-beta (RELM-β). Testing RELM-β’s role, we generated Muc2−/−/Retnlb−/− mice, finding that RELM-β deficiency significantly attenuated colitis development and symptoms compared with Muc2−/− mice. RELM-β expression in Muc2−/− mice strongly induced the production/secretion of the antimicrobial lectin RegIIIβ, that exerted its microbicidal effect predominantly on Gram-positive Lactobacillus species. Compared with Muc2−/−/Retnlb−/− mice, this worsened intestinal microbial dysbiosis with a selective loss of colonic Lactobacilli spp. in Muc2−/− mice. Orally replenishing Muc2−/− mice with murine Lactobacillus spp., but not with a probiotic formulation containing several human Lactobacillus spp. (VSL#3), ameliorated their spontaneous colitis in concert with increased production of short-chain fatty acids. These studies demonstrate that the goblet cell mediator RELM-β drives colitis in Muc2−/− mice by depleting protective commensal microbes. The ability of selective commensal microbial replacement to ameliorate colitis suggests that personalized bacterial therapy may prove beneficial for treatment of UC.

Introduction

Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) characterized by severe mucosal inflammation and ulceration in the large intestine. This debilitating disease is thought to develop due to exaggerated bacterial stimulation of the mucosal immune system.1 This may reflect changes in the gut microbiota, as the microbial populations of UC patients are known to be dysbiotic, often showing less biodiversity, fewer beneficial microbes, and increased pathobiont numbers than the microbiota of healthy individuals.2, 3 Moreover, UC patients often display structural or functional defects in their normally protective colonic mucosal barriers. This includes the intestinal mucus barrier, which is largely dependent on the release of goblet cell-derived mucin (Muc2), the major secretory mucin within the gastrointestinal tract.4 A highly glycosylated protein, upon its release, Muc2 is hydrated, forming the mucus layer that prevents microbes as well as luminal antigens from contacting the epithelial surface.5, 6 Several studies on inflamed UC patient tissues have shown reduced goblet cell numbers, and a thinner than normal mucus layer.7 These changes are not necessarily secondary to disease, but may instead represent a primary defect since functional impairments in mucus are observed in some IBD patients even with inactive disease and in mouse models of IBD prior to overt inflammation.8, 9, 10 Correspondingly, mice that lack Muc2, or suffer missense mutations in Muc2 that impair its release and function develop spontaneous colitis that depends on the presence of gut microbes.11, 12 Although clearly demonstrating that impaired function and loss of goblet cells predisposes to colitis, it remains uncertain whether additional or concurrent changes in goblet cell function also have a role. Goblet cells produce important mucosal defense factors like trefoil factor 3 (TFF3) and resistin-like molecule-beta (RELM-β). RELM-β was initially thought to have a role in insulin resistance in rodents; however, it was subsequently found to impact immune regulation and host defense against intestinal nematode infections.13, 14 RELM-β is secreted apically into the intestinal lumen15 and regulates susceptibility to intestinal inflammation by promoting mucosal barrier integrity.16 RELM-β expression is induced by commensal colonization in germ-free mice17 and its secretion is known to be upregulated in several animal models of gut inflammation.18, 19, 20 These include dextran sodium sulfate colitis where RELM-β was found to leak into the colonic lamina propria, activating macrophages to secrete the cytokine tumor necrosis factor-α.21 Interestingly, although RELM-β has been shown to regulate the expression of the antimicrobial lectins RegIIIβ and RegIIIγ, it is unclear whether it has any role in shaping the gut microbiota.

Based on preliminary studies showing that RELM-β was strongly upregulated in the colons of colitic Muc2-deficient (−/−) mice, we tested its role during the spontaneous colitis that develops in these mice. We hypothesized that in the absence of the mucus barrier, goblet cells would release RELM-β to protect the colonic mucosal surface by upregulating RegIIIβ and RegIIIγ to create an antimicrobial zone overlying the epithelium. To test this, we generated mice lacking both Muc2 and RELM-β and compared their colitis development with that in Muc2−/− mice. Although our hypothesis was partially confirmed, as RegIIIβ expression was dramatically induced in Muc2−/− mice but largely lacking in Muc2−/−/Retnlb−/− mice, its antimicrobial activity led to a dysbiotic gut microbiome deficient in Lactobacillus spp. Over time, this led to a dramatically worsened clinical course in the Muc2−/− mice that was reversible by targeted replacement by murine, but not human-derived Lactobacillus spp. These studies demonstrate that it is the goblet cells themselves that drive the colitis in Muc2−/− mice, by inducing a RELM-β-dependent intestinal microbial dysbiosis.

Results

Muc2−/− mice rapidly develop spontaneous colitis

Assessment of Muc2−/− mice raised in our facility confirmed previous reports of spontaneous colitis development under physiological conditions. While Muc2−/− mice appeared completely healthy just after weaning (1 month), as they aged, they developed progressive diarrhea along with sporadic rectal prolapse (RP) (Figure 1a and b). Once killed, their colons were found to be thickened and reddish in color, containing soft rather than formed stool. Histological analysis revealed that compared with age-matched C57BL/6 mice, 2–month-old Muc2−/− mouse colon tissues showed overt crypt hyperplasia, occasional crypt abscesses, as well as modest inflammatory cell infiltration and submucosal edema (Figure 1c). Staining with Periodic acid-Schiff revealed markedly reduced acidic and neutral staining of mucins in the colons of Muc2−/− mice (Figure 1d), however, some staining was still evident; indicating the presence of other mucins.

Figure 1
figure1

Clinical features of spontaneous colitis in Muc2−/− mice. (a) Macroscopic examination showed that the colons of Muc2−/− mice were swollen and contained soft and loose stool when compared to the colons of C57BL/6 mice. (b) Rectal prolapse typically manifests in Muc2−/− mice aged between 1 months to 4 months. (c) H&E staining of colon tissues obtained from Muc2−/− mice aged 2 months demonstrating significant inflammation characterized by inflammatory cell infiltration, crypt hyperplasia and abscesses and submucosal edema (original magnification × 200). (d) Staining for acidic (Alcian blue) and neutral (PAS) carbohydrates showed significant loss of mucin production in Muc2−/− mice. (e) Mucin gene transcription for Muc3, Muc5AC, Muc6, and Muc13 showed no significant differences between C57BL/6 and Muc2−/− mice. (f) In contrast, when analyzed for the transcription of other goblet cell-derived factors such as Retnlb and Tff3, the transcription of Retnlb was significantly higher in Muc2−/− mice. (g) Immunostaining also revealed increased positive staining for RELM-β in Muc2−/− mice whereas the staining for TFF3 was similar to that in C57BL/6 mice (original magnification × 630). n5 per each group, Student’s t-test, ***P<0.0001, A, crypt abscess; H&E, hematoxylin and eosin; I, inflammatory cell infiltration; Lu, intestinal lumen; M, mucosa; Muc, mucin; O, edema; PAS, Periodic acid-Schiff; RELM-β, resistin-like molecule-beta; SM, sub-mucosa.

PowerPoint slide

To assess whether the remaining Periodic acid-Schiff staining reflected compensatory increases in other mucins, transcript levels for Muc3, Muc5AC, Muc6, and Muc13 were assayed. The transcription of these mucin genes in Muc2−/− mice was similar to levels in C57BL/6 mice, suggesting no overt compensatory response (Figure 1e). As goblet cells not only secrete mucins, but also RELM-β and TFF3, we next analyzed their gene transcription. As shown in Figure 1f, a significant 290-fold increase in Retnlb gene transcription was observed in Muc2−/− mice as compared with C57BL/6 mice. A dramatic increase in RELM-β-positive immunostaining was also observed in Muc2−/− mice, localizing solely to goblet cells (Figure 1g). In contrast, little if any RELM-β staining was seen in age-matched C57BL/6 mice. The dramatic elevation in Retnlb was selective, as no significant changes in Tff3 transcript levels, or the TFF3 protein were identified in Muc2−/− mice, as compared with C57BL/6 mice. Thus, in the absence of Muc2, the goblet cell mediator RELM-β is strongly upregulated.

Spontaneous colitis symptoms are reduced in Muc2−/−/Retnlb−/− mice

To determine whether RELM-β had any role in the spontaneous colitis of Muc2−/− mice, we generated a mouse strain (Muc2−/−/Retnlb−/−) lacking both Muc2 and RELM-β. The F1 and F2 progeny obtained from crossbreeding Retnlb−/− and Muc2−/− mice were genotyped (Supplementary Figure S1A online) using published primers.12, 22 Colon tissues from the parental as well as Muc2−/−/Retnlb−/− mouse strains were immunostained for Muc2 and RELM-β. As expected, Muc2 was readily detected in the goblet cells of C57BL/6 and Retnlb−/− mice, but was undetectable in Muc2−/ or Muc2−/−/Retnlb−/− mice (Supplementary Figures S1B and S1C). Similarly, when colon tissues were stained for RELM-β, only Muc2−/− mice displayed positive staining, whereas it was not detected in healthy C57BL/6 mice, or in mouse strains lacking Retnlb (Supplementary Figures S1D and S1E).

Once generated, the Muc2−/−/Retnlb−/− mice were monitored for breeding success, changes in body weight and clinical symptoms such as RP and stool consistency. Similar to C57BL/6 mice, Muc2−/−/Retnlb−/− mice were very fertile, producing 4–5 litters of normal size (8–10 pups) over their reproductive lives. In comparison, Muc2−/− mice only produced 3–4 litters of smaller size (4–8 pups). Moreover, significant differences in body weights were noted between mouse strains as early as 2 months of age. Compared with C57BL/6 mice, Muc2−/− mice were smaller and weighed significantly less (11, 4, and 14%) at 2, 4, and 6 months of age, respectively (Figure 2a). In contrast, Muc2−/−/Retnlb−/− mice weighed significantly more (8, 6, and 5%) than C57BL/6 mice at these time points (Figure 2a).

Figure 2
figure2

Increase in clinical symptoms of colitis in Muc2−/− mice compared with Muc2−/−/Retnlb−/− mice. (a) Body weights of Muc2−/− mice recorded at 2, 4, and 6 months of age and the results shown as the percent (%) change in body weight after normalization to body weights of C57BL/6 mice (left and middle panel) and Muc2−/−/Retnlb−/− mice (right panel) at respective time points. (b) Manifestation of rectal prolapse according to its age of appearance (<2, 2–4, or >4 months) is higher in Muc2−/−mice when compared with Muc2−/−/Retnlb−/− mice. (c) The percentage of mice with loose stools is also higher Muc2−/− mice when compared with Muc2−/−/Retnlb−/− mice. n15 mice were used for each clinical symptom measured. Two-way ANOVA analysis followed by Bonferroni’s post-test was used to calculate time-dependent significance between each group of mice, ***P<0.0001. ANOVA, analysis of variance; Muc, mucin; RELM-β, resistin-like molecule-beta.

PowerPoint slide

As Muc2−/− mice aged, they displayed overt symptoms of spontaneous colitis. Prior to reaching 2 months of age, 6% developed overt RP (requiring euthanization), while 17% of the original cohort developed RP between 2 and 4 months of age. Another 17% developed RP between 4 and 6 months of age, reaching a total 40% of Muc2−/− mice developing RP by 6 months of age. In contrast, only 17% of Muc2−/−/Retnlb−/− mice developed RP over the same time course, with 3% developing it before 2 months, 5% between 2 and 4 months and 9% between 4 and 6 months of age (Figure 2b). Furthermore, when the two mouse strains were analyzed for stool consistency over their first 6 months, 59% of Muc2−/− mice developed loose stools, vs. only 30% of Muc2−/−/Retnlb−/− mice (Figure 2c). Overall, Muc2−/−/Retnlb−/−mice suffered significantly fewer colitic symptoms (RP and loose stools) as compared with Muc2−/− mice (P<0.05, χ2-test), indicating a pro-colitic role for RELM-β expression in Muc2−/− mice under physiological conditions.

RELM-β expression worsens colonic crypt pathology in 4 months old Muc2−/− mice

Since almost half the Muc2−/− mice required killing before 6 months of age, we decided to focus future studies on mice at 2 and 4 months of age. Microscopic analysis of hematoxylin and eosin stained colon sections at 2 months revealed modest submucosal edema, crypt hyperplasia as well as mucosal inflammation in both mouse strains. Immune/inflammatory cell infiltration was widespread in the Muc2−/− mice but less overt in the Muc2−/−/Retnlb−/− mice, whereas crypt hyperplasia was greater in the Muc2−/−/Retnlb−/− mice, with total pathology scores roughly similar between the two groups (3.8±0.6 vs. 4.8±0.8; Figure 3a). Between 2 and 4 months of age, colonic pathology in the Muc2−/−/Retnlb−/− mice increased only modestly to 7.2±0.5, largely due to the increased immune/inflammatory cell infiltration. In contrast, colonic tissue damage was dramatically greater in 4–month-old Muc2−/− mice. Although edema, crypt hyperplasia, and inflammatory cell infiltration were all increased, their most significant pathological features reflected increased crypt epithelial damage as well as crypt abscesses. As compared with Muc2−/−/Retnlb−/− mice, Muc2−/− crypts were highly irregular and distorted in shape, while intercryptal spaces were greatly dilated. Crypt abscesses containing neutrophils and necrotic epithelial cells were rare in Muc2−/−/Retnlb−/− mice, but very frequent in Muc2−/− mice (Figure 3b), along with large numbers of neutrophils found within the crypt epithelium. When quantified, colonic pathology increased a dramatic 250% (12.2±1.6) in Muc2−/− mice by 4 months of age, reaching a level significantly (P<0.001) greater than that of Muc2−/−/Retnlb−/− mice (Figure 3c).

Figure 3
figure3

Colonic crypt pathology worsens over time in Muc2−/− mice. H&E stained colonic cross sections from (a) 2- and (b) 4-month-old Muc2−/− and Muc2−/−/Retnlb−/− mice. Both mouse strains show a significant increase in colonic histopathology between 2 and 4 months of age, however, the histological damage was more severe in Muc2−/−mice in comparison with Muc2−/−/Retnlb−/− mice. (c) Bar graphs represents histological scoring of colon tissues in C57BL/6, Retnlb−/−, Muc2−/− and Muc2−/−/Retnlb−/− mice aged 2 and 4 months. A double blinded scoring system was used based on following criteria: (i) hyperplasia (0, no change; 1, 1–50%; 2, 51–100%; 3, >100%), scored as percentages above the height of C57BL/6 mice; (ii) crypt abscess (0, no abscess; 1, few crypts exhibit abscess; 2, about half of the crypts exhibit abscess; 3, over 70% of the crypts exhibit abscesses); (iii) epithelial integrity (0, no pathological changes detectable; 1, few cells slough; 2, epithelial surface rippled; 3, severely disrupted/damaged, large amount of epithelial cell sloughing); (iv) edema (0, no change; 1, mild change; 2, moderate change, and 3, profound change) and (v) mononuclear and polymorphonuclear cells (0, no change; 1, <20; 2, 21–50; 3, 51–70; 4, >70). n15 Mice, original magnification × 200. Two-way ANOVA, ***P<0.0001, (Mean±s.e.m.). ANOVA, analysis of variance; I, inflammatory cell infiltration; M, mucosa; Muc, mucin; O, edema; RELM-β, resistin-like molecule-beta; SM, sub-mucosa.

PowerPoint slide

Muc2−/− and Retnlb−/−/Muc2−/− mice display only modest differences in colonic inflammation

The differential progression of the colitis observed in Muc2−/− and Muc2−/−/Retnlb−/− mice led us to investigate whether it reflected differences in inflammatory and immune cell recruitment to the colon. Immunostaining for T lymphocytes (CD3+), macrophages (F4/80+), and neutrophils (Ly6g+) revealed that all three cell types were in greater abundance in the colons of Muc2−/− and Muc2−/−/Retnlb−/− mice, as compared with C57BL/6 tissues (Figure 4a–c). At 2 months of age, T lymphocyte numbers were modestly, but significantly higher in Muc2−/− mice as compared with Muc2−/−/Retnlb−/− mice, whereas neutrophil and macrophage numbers were similar. Interestingly, by 4 months of age, macrophage numbers remained constant, whereas T lymphocyte and neutrophil numbers increased in the tissues of Muc2−/−/Retnlb−/− mice to levels similar to Muc2−/− mice, despite their comparatively reduced tissue pathology.

Figure 4
figure4

Inflammatory cell responses are similar in Muc2−/− and Muc2−/−/Retnlb−/− mice. Colon tissue sections collected from 2- and 4-month-old mice were immunostained for (a) T lymphocytes (CD3), (b) neutrophils (Ly-6 g) and (c) macrophages (F4/80). Bar graphs represent the average number of positive cells identified per field (× 630). Tissues were also analyzed for gene transcription of pro- and anti- inflammatory cytokines in Muc2−/− and Muc2−/−/Retnlb−/− mice aged (d) 2 and (e) 4 months of age. n=12 Mice were analyzed per each group, original magnification × 630. MANOVA **P<0.001, ***P<0.0001. MANOVA, multivariate analysis of variance; Muc, mucin.

PowerPoint slide

We next examined whether any overt differences in inflammatory cytokine gene transcription (tumor necrosis factor-α, interferon-γ, interleukin (IL)-6, IL-17F, IL-23) could explain the worsened outcomes in the Muc2−/− mice. Surprisingly, we noted only minimal differences in transcript levels of these genes between Muc2−/− mice and Muc2−/−/Retnlb−/− mice at both 2 and 4 months (Figure 4d and e). The only notable differences were significantly greater IL-22 gene transcription in 2–month-old Muc2−/−/Retnlb−/− mice vs. Muc2−/− mice, whereas both IL-17A and IL-22 gene transcription were comparatively upregulated in 4-month-old Muc2−/− mice (Figure 4d and e). Thus, while modest differences were noted in the immune/inflammatory response between the two mouse strains, the exaggerated epithelial pathology seen in the Muc2−/− mice appears to likely depend on other factors.

RELM-β induces antimicrobial lectin expression in the colons of Muc2−/− mice

To determine whether the exaggerated colitis in the Muc2−/− mice could instead reflect abnormal host–microbe interactions, we analyzed gene transcript levels for several antimicrobial factors, including the lectins RegIIIβ and RegIIIγ, defensins (β-defensin 1 and β-defensin 3) and inducible nitric oxide synthase (iNOS). Although only minor differences in defensins and iNOS transcript levels were noted between Muc2−/− and Muc2−/−/Retnlb−/− mice, 2-month-old Muc2−/− mice showed a 1,600- and 340-fold increase in RegIIIβ and RegIIIγ gene transcripts as compared with Muc2−/−/Retnlb−/− mice (Figure 5a). Interestingly, while RegIIIβ and RegIIIγ gene transcripts ultimately did show a modest increase in Muc2−/−/Retnlb−/− mice at 4 months of age, these genes were still transcribed at 36- and sixfold higher levels in age-matched Muc2−/−mice (Figure 5b). Based on the dramatic elevation of the RegIIIβ gene and the tools available to study this lectin,23 we focused our subsequent analysis on its expression and function.

Figure 5
figure5

RELM-β induced upregulated transcription of antimicrobial lectin genes in Muc2−/− mice. Antimicrobial gene transcription analysis identified significantly increased transcription of lectin genes RegIIIβ and RegIIIγ in (a) 2 month and (b) 4 month old Muc2−/− mice in comparison to Muc2−/−/Retnlb−/− mice. (c) Sections of colons stained for RegIIIβ also revealed strong staining on the colonic mucosal surface of 2- and 4-month-old Muc2−/− mice. (d) Stool samples probed to detect RegIIIβ also exhibited thick western blot bands in the samples from Muc2−/− mice suggesting the protein is secreted into the intestinal lumen. (e) Colon sections of 4 months old Muc2−/−mice co-immunostained with RegIIIβ and E-cadherin reveal epithelial production of RegIIIβ. (f) RT-PCR analysis on cDNA obtained from CMT-93 cells demonstrates upregulated transcription of RegIIIβ and RegIIIγ genes in cells incubated with recombinant RELM-β (100 ng ml−1). For a and b n=4 mice per group, for d n=2–3 per group, and e and f n=3 per group, repeated twice. Original magnification × 200 for c and × 650 for e; representative results were shown for gene transcription and Student’s t-test and MANOVA was used to get statistical significance. cDNA, complementary DNA; MANOVA, multivariate analysis of variance; Muc, mucin; RELM-β, resistin-like molecule-beta; RT-PCR, reverse transcriptase–PCR.

PowerPoint slide

Corresponding with RegIIIβ’s dramatically upregulated transcription, intense and widespread RegIIIβ immunostaining localized to the colonic epithelium was found in 2-month-old Muc2−/− mice, but not in Muc2−/−/Retnlb−/− mice. By 4 months, modest RegIIIβ staining was also observed in the Muc2−/−/Retnlb−/− mice. Although RegIIIβ staining in 4-month Muc2−/− mice was reduced compared with levels at 2 months, it was still dramatically stronger than that seen in Muc2−/−/Retnlb−/− mice (Figure 5c). Additional western blotting of colonic crypts and whole tissue lysates demonstrated thick RegIIIβ bands from Muc2−/− mouse tissues at both 2 and 4 months of age, whereas the RegIIIβ signal was minimal from Muc2−/−/Retnlb−/− mouse tissues (Supplementary Figure S2A). To determine whether RegIIIβ was secreted into the colonic lumen, stool samples from Muc2−/− mice were probed for RegIIIβ by western blotting. RegIIIβ was readily detected in the stool of Muc2−/− mice (Figure 5d), but not Muc2−/−/Retnlb−/− mice. Additional western blotting on these same Muc2−/− stool lysates confirmed distinct bands of RELM-β, whereas it was absent from Retnlb−/− and Muc2−/−/Retnlb−/− stool (Supplementary Figure S2B). To clarify the cellular source of the RegIIIβ, co-staining of colon sections revealed substantial RegIIIβ staining in cells that were also positive for the epithelial cell marker E-cadherin, confirming epithelial cells as the major source of RegIIIβ (Figure 5e). To determine whether RELM-β could directly induce RegIIIβ and RegIIIγ lectins, mouse epithelial CMT-93 cells were treated with recombinant RELM-β. At 4 h post treatment, a significant 2.7- and sixfold increase in RegIIIβ and RegIIIγ transcription (respectively) was observed in RELM-β-treated cells as compared with untreated cells (Figure 5f). Overall, these results demonstrate that RELM-β exerts significant control over epithelial expression of the antimicrobial lectin RegIIIβ in the colons of Muc2−/− mice.

Commensal microbial dysbiosis in Muc2−/− mice is exaggerated in the presence of RELM-β

Notably, Muc2−/− mice were recently shown to carry an aberrant gut microbiome that potentially promotes their colitis.24 Considering their significant secretion of the antimicrobial lectin RegIIIβ, we assessed whether it impacted their microbiota. We first analyzed colon tissues for bacterial localization using a eubacterial (EUB) fluorescent in situ hybridization (FISH) probe that detects all bacteria. Significant numbers of adherent bacteria were noted on the colonic mucosal surface of both Muc2−/− and Muc2−/−/Retnlb−/− mice, along with staining in the colonic submucosa suggesting bacterial translocation (Figure 6a). Quantitation of total commensal microbes in the stool by 4’,6’-diamidino-2-phenylindole staining revealed no significant differences between the two mouse strains (Figure 6b). Using primers specific for 16S ribsosomal RNA, we confirmed that Muc2−/− mice possess an aberrant microbiota as compared to C57BL/6 mice, including reduced levels of Lactobacilli (Supplementary Figure S3A). However, when we compared the colon contents of Muc2−/− and Muc2−/−/Retnlb−/− mice at the phyla level, Bacteriodetes, and Firmicutes levels were similar, although there was a trend towards more γ-Proteobacteria in the Muc2−/−mice. In contrast, when the colon contents were analyzed at the species level (Segmented Filamentous Bacteria, Lactobacillus spp. and Clostridia spp.), the Muc2−/−/Retnlb−/− mice were found to carry significantly more Gram+ve Lactobacilli bacteria (8.5 and 3 fold) than the Muc2−/− mice at 2 and 4 months respectively (Figure 6c and d). The retention of Lactobacilli in the colons of Muc2−/−/Retnlb−/− mice was confirmed by FISH staining, using probes designed to detect several Lactobacilli spp. (Supplementary Figure S3B).

Figure 6
figure6

Altered commensal microbe populations in Muc2−/− and Muc2−/−/Retnlb−/− mice. (a) FISH hybridization using a probe recognizing all bacteria, revealed microbial adherence and invasion into the mucosa and submucosal tissues in both Muc2−/− and Muc2−/−/Retnlb−/− mice. (b) DAPI counting of bacteria demonstrated similar levels of total microbes between the two mouse genotypes. DNA extracted from colon contents of Muc2−/− and Muc2−/−/Retnlb−/− mice showed significant changes in the makeup of the microbiota at the species level in (c) 2-month and (d) 4-month-old mice. Results were shown as an average of three independent experiments with n=3–4 per group. T-tests were used to calculate the significance between each taxonomic group from stool samples of Muc2−/− and Muc2−/−/Retnlb−/− mice ***P<0.0001. DAPI, 4’,6’-diamidino-2-phenylindole; FISH, fluorescent in situ hybridization; Muc, mucin.

PowerPoint slide

Considering the dysbiotic microbiota seen in the Muc2−/− mice, we asked whether it was exposure to these microbes that drove the upregulated RELM-β expression. To test this, 12-week old Muc2−/− mice were given peroral treatment of 200 μl of an antibiotic mixture for 8 days. A significant reduction in RELM-β immunoreactive goblet cells was noted in colonic sections of antibiotic treated mice in comparison to untreated mice confirming a key role for the microbiota in driving RELM-β expression (Supplementary Figure S3C).

RELM-β induced RegIIIβ mediates the antimicrobial effect on Lactobacilli spp.

While our data indicated that Muc2−/− mice carried significantly fewer Lactobacilli than Muc2−/−/Retnlb−/− mice, the basis for this microbial dysbiosis was unclear. Using two Lactobacilli isolates from wildtype mice showing close resemblance to L. gasseri and L. johnsonii sub-species respectively, we tested whether RELM-β exerted any direct antimicrobial activity but found no effect (not shown). We next examined the lectin RegIIIβ, testing the effects of recombinant RegIIIβ as well as crypt supernatants obtained from 2 and 4 month old Muc2−/− and Muc2−/−/Retnlb−/− mice. Western blotting confirmed high levels of the RegIIIβ lectin only in the supernatants of the Muc2−/− mice (Figure 7a). Upon incubating the mouse Lactobacilli isolates with the crypt supernatants, the Muc2−/−/Retnlb−/− supernatants at 2 months promoted bacterial growth, while at 4 months, they showed only minimal antimicrobial activity against Lactobacilli (Figure 7b and c). In contrast, significant bactericidal effect was observed with supernatants obtained from Muc2−/− mice (at both 2 and 4 months), as well as with the recombinant RegIIIβ, confirming it is likely responsible for the ability of Muc2−/− mouse lysates to kill Lactobacilli.

Figure 7
figure7

Antimicrobial effect of RegIIIβ on the growth of mouse commensal Lactobacilli. (a) Western blot to detect RegIIIβ identified the protein in the supernatants of crypts obtained from Muc2−/− but not Muc2−/−/Retnlb−/− mice (2 and 4 months). These supernatants were also used for incubation with (b) Lactobacillus isolate 1 and (c) isolate 2. Muc2−/− supernatants exhibited significant antimicrobial activity against these isolates, whereas little antimicrobial activity was seen with supernatants obtained from Muc2−/−/Retnlb−/− mice. N=2–3 mice were used for each group and experiments were repeated three times. ANOVA *P<0.05, **P<0.001 and ***P<0.0001. ANOVA, analysis of variance; Muc, mucin.

PowerPoint slide

Targeted introduction of mouse Lactobacilli spp. ameliorates colitis in Muc2−/− mice

Strains of Lactobacilli have previously proven beneficial in several models of colitis, so we hypothesized that their loss could contribute to the exaggerated colonic pathology seen in Muc2−/− mice at 4 months of age. To clarify this, 3 month old Muc2−/− mice were given drinking water containing either our murine Lactobacilli isolates (1 and 2) or a commercial source of human probiotics (VSL#3) that contains a mixture of three Lactobacilli spp. The mice were then assessed for colitis at 4 months of age. Hematoxylin and eosin staining and colon pathology scoring of VSL#3 treated mice noted a similarly severe colitis in the untreated and VSL#3 treated mice (Figure 8a). In addition, VSL#3 treated mice showed frequent RP and watery stools similar to untreated mice (Figure 8b and c). In contrast, upon analyzing the Muc2−/− mice treated with the murine Lactobacilli isolates, we noted a significant reduction in crypt abscesses and hyperplasia, submucosal edema, and mononuclear cell infiltration as well as improved maintenance of epithelial integrity, as compared to untreated Muc2−/− mice (Figure 8d). In addition, the Lactobacilli treated mice did not develop RP and none manifested diarrheic symptoms, whereas 15.3% of untreated mice exhibited RP and 55% demonstrated loose stools (Figure 8e and f). To confirm that administration of the Lactobacilli isolates altered the microbiome, 16s ribsosomal RNA analysis of colon contents demonstrated a significant 3.5-fold increase in Lactobacilli levels in mice treated with Lactobacilli but not with VSL3 treatment (Figure 8g). Furthermore, FISH hybridization on stool samples also showed a fourfold increase in Lactobacilli numbers in the Lactobacilli-treated Muc2−/− mice as compared with untreated mice (Supplementary Figure S4A). A dramatic reduction in RELM-β and RegIIIβ immunostaining was observed in Lactobacilli-treated mice but not in VSL3 or untreated mice suggesting that the Lactobacilli suppressed antimicrobial responses in the Muc2−/− mice (Supplementary Figure S4B). Interestingly, when IL-17A and IL-22 gene transcript levels were analyzed from colon tissues, a modest increase in IL-17A and a significant increase in IL-22 was observed in Lactobacilli-treated mice (Figure 8h). Taken together, these results indicate that targeted replacement of murine-derived Lactobacilli can ameliorate colitis in Muc2−/− mice.

Figure 8
figure8

Murine Lactobacilli treatment reduces spontaneous colitis in 3- to 4-month-old Muc2−/− mice. (a) Left panel: H&E sections of colon tissues obtained from 4-month-old Muc2−/− mice treated with the human probiotic mixture VSL#3 in their drinking water for one month (started at age 3 months). Right panel: Histological scoring of H&E stained colonic tissues showed no significant differences in histopathology between treated and untreated Muc2−/− mice (b) similarly, no differences were observed in appearance of rectal prolapse and (c) stool consistency between the treated and untreated groups. However, (d) Muc2−/− mice treated with a combination of mouse commensal Lactobacilli isolate 1 and 2, showed overt protection from colitis as revealed by H&E staining. In addition, no (e) rectal prolapses as well as (f) normally formed stools were observed in Lactobacilli treated mice. (g) Successful colonization was confirmed as colon contents of treated and untreated mice revealed increased colonization with commensal Lactobacilli isolate 1 and 2 in the Lactobacilli treated mice but not with human VSL3 treated mice. (h) RT-PCR analysis on cDNA obtained from Lactobacilli treated mice demonstrated a significant increase in the transcription of IL-22 in comparison to untreated mice n=5 per group repeated twice for (ag), n=4 for (h). Original magnification × 200. Student’s t-test and One-way ANOVA was used for b, c, e, f, and g, respectively ***P<0.0001, **P<0.001, *P<0.05, A, crypt abscess; ANOVA, analysis of variance; cDNA, complementary DNA; H&E, hematoxylin and eosin; I, inflammatory cell infiltration; IL-22, interleukin-22; Lu, intestinal lumen; M, mucosa; Muc, mucin; O, edema; RT-PCR, reverse transcriptase–PCR; SM, sub-mucosa.

PowerPoint slide

Upregulation of short-chain fatty acids in the colons of Lactobacilli treated Muc2−/− mice

To understand how Lactobacilli treatment suppressed colitis in Muc2−/− mice, we assayed the production of short-chain fatty acids (SCFA) in the colon contents of these mice. Specific bacterial species such as Lactobacilli are primary degraders of insoluble polysaccharides in the gut. This carbohydrate fermentation under anaerobic conditions produces SCFAs such as acetate, propionate, and butyrate, which protect against colitis and promote gut homeostasis.25 Our results demonstrated increased production of propionate and acetate in Lactobacilli-treated mice when compared with untreated Muc2−/− mice (Figure 9a). These results suggest that one mechanisms by which Lactobacilli spp. treatment attenuates colitis in Muc2−/− mice is by increasing the production of SCFA.

Figure 9
figure9

Increased short-chain fatty acid levels in Lactobacillus treated mice. (a) Colon contents analyzed for SCFA levels using gas chromatography demonstrated increased levels of acetic and propionic acid in Lactobacilli treated Muc2−/− mice in comparison with untreated Muc2−/− mice. Results shown represent an average of n=6 mice. Student’s t-test *P<0.05. Muc, mucin; SCFA, short-chain fatty acid.

PowerPoint slide

Discussion

Intestinal goblet cells secrete several mediators including TFF3 and RELM-β, but they are best known for secreting the Muc2 that forms the protective intestinal mucus layer.26 In fact, several recent studies have highlighted the beneficial role this barrier has by limiting direct bacterial contact with the intestinal mucosa. Notably, mice impaired in the release of Muc2 are predisposed to developing colitis. The original goal of this study was to determine how intestinal goblet cells respond in the absence of Muc2, and whether they compensate by releasing other mediators in the context of colitis. Confirming previous studies, we found that after weaning, Muc2−/− mice develop colitis, in concert with a dramatic increase in the secretion of another goblet cell mediator, RELM-β. By generating mice lacking both Muc2 and RELM-β, we determined that compared with Muc2−/− mice, Muc2−/−/Retnlb−/− mice are delayed in their colitis development. Among its roles, RELM-β upregulated RegIIIβ, an antimicrobial lectin that efficiently kills Gram-positive bacteria, causing a microbial dysbiosis that worsens the colitis in Muc2−/− mice. Furthermore, we showed that targeted treatment with mouse commensal Lactobacilli in Muc2−/− mice can dramatically reduce their colitis symptoms and pathology. In contrast, treatment with human probiotics was unable to resolve the colitis, highlighting the value of targeted bacterial therapeutic intervention.

Members of the resistin family were previously shown to promote insulin resistance and were linked to obesity, however, recent studies have highlighted their role as inflammatory mediators in the intestine.22, 27, 28 High levels of serum resistin were reported in IBD patients suggesting it as a possible marker for intestinal inflammation.29, 30 Although RELM-β expression was found highly induced in colonic goblet cells during several models of colitis, its role has remained unclear. We, and others, have reported the transcription of lectin genes increasing concurrently with the expression of RELM-β during infectious or chemically induced colitis;22, 31 however, its potential to regulate the makeup of the gut microbiome was untested. We now show that RELM-β promotes colitis by inducing changes in commensal bacteria through the induction of the antimicrobial lectin RegIIIβ. Of note, the modest induction of RegIIIβ seen in Muc2−/−/Retnlb−/− mice indicates that there are RELM-β-independent pathways regulating its expression, potentially reflecting the upregulated transcription of IL-22 observed in the Muc2−/−/Retnlb−/− mice. IL-22 was previously demonstrated to modulate antimicrobial molecule expression during intestinal inflammation,32, 33, 34 including RegIIIβ and RegIIIγ induction.

Antimicrobial lectins such as RegIIIα, β, and γ have been previously shown to protect gut homeostasis, potentially by spatially segregating the microbiota from the intestinal epithelium.35, 36, 37 Notably, we found RegIIIβ was upregulated in Muc2−/− mice just after weaning, concurrent with a relative reduction in Lactobacilli, at least 1 month prior to overt colitis development. Thus, it takes time for the loss of Lactobacilli to promote the exaggerated pathology suffered by Muc2−/− mice; however, the ability of oral administered Lactobacilli to ameliorate their colitis confirms their loss has a key role in the colitis development of Muc2−/− mice. It was intriguing that RELM-β expression appeared to primarily affect Lactobacilli. This may reflect the susceptibility of these microbes to RegIIIβ and other lectins, and/or their localization within the colon—potentially near the colonic epithelium. Notably, strains of Lactobacilli from humans have been well studied for their potential beneficial effects within the gastrointestinal tract. Treatment with Lactobacillus rhamnosus GG has been shown to be safe and potentially beneficial in maintaining remission in some UC patients.38 Similar treatment in combination with Lactobacillus acidophilus was used in a clinical study to treat UC (Ref: NCT00374725), while L. reuterii administration was found to protect against spontaneous enterocolitis in IL-10−/− mice.39

Curiously, the effectiveness of Lactobacilli in large clinical trials has been mixed, potentially indicating only a subset of patients show benefit. This may suggest that probiotics only prove effective when they take up prolonged residence within the host intestine. Exactly how probiotic Lactobacilli confer protection to the host is still under study, but the ability of human-derived Lactobacilli to increase butyrate production by Clostridia species is one potential mechanism.40 In contrast, Lactobacilli strains derived from mice are less studied, and we found that their supplementation to Muc2−/− mice significantly increased acetate and propionate levels, but not butyrate. This increase in SCFA may be a key factor promoting mucosal healing in the Lactobacilli-treated Muc2−/− mice. Notably, acetate and propionate have gained considerable attention due to their role in glucose metabolism and their ability to suppress NF-κB, making them potentially useful in the treatment of IBD.41, 42 Moreover, our results showing an increase in the gene transcript levels of IL-22 in Lactobacilli-treated group suggests a possible wound healing role of this cytokine during intestinal inflammation.43, 44 Thus, the transcription of IL-22 along with the milieu of elevated protective SCFA, would have significantly contributed to limit colonic tissue damage and colitis observed in Lactobacilli-treated Muc2−/− mice. However, we do not exclude other possible reported mechanisms for the benefits of Lactobacilli treatment, such as competitive exclusion of pathogenic microbes, strengthening of tight junction proteins, and/or regulation of cytokine expression.45, 46

In conclusion, these findings highlight a new role for intestinal goblet cells. Not only are they key protective cells that maintain the intestinal mucus barrier, but they can also act as potent drivers of intestinal inflammation, in this study, through the ability of RELM-β to promote commensal microbial dysbiosis. Although Muc2 deficiency on its own altered the gut microbiome, it was the additional actions of RELM-β that exaggerated the dysbiosis and worsened colitis in these mice. RELM-β did this by directly upregulating RegIIIβ expression that exerted its antimicrobial effects on Lactobacilli. Overall, these results not only provide insight into how altered goblet cell function can contribute to intestinal inflammation, but also demonstrate that specifically identifying depleted commensal bacterial species in UC patients and selectively reconstituting the same species could prove potentially therapeutic.

Methods

Mice. Mucin 2 (Muc2) and Resistin like molecule beta (Retnlb) deficient mice (C57BL/6 background) were crossbred to generate Muc2−/−/Retnlb−/− mice. Genotyping was performed using a DNA extraction kit (Qiagen, Toronto, Ontario, Canada) followed by amplification of wild-type and mutated Muc2 and Retnlb alleles using PCR and agarose gels. Primer sequences were obtained from previous publications.12, 47 All mice (including wild-type C57BL/6) were raised in-house, in sterilized, filter-topped cages, handled in biosafety cabinets, and fed autoclaved food and water under specific pathogen-free conditions. The protocols used were approved by the University of British Columbia’s Animal Care Committee and in direct accordance with guidelines drafted by the Canadian Council on the Use of Laboratory Animals.

Tissue collection. Mice were anesthetized with isofluorane and killed via cervical dislocation. For microbiota analysis, fresh colon contents were collected and transferred into cryogenic vials. For histology, 0.5-cm sections of distal colon were immediately placed in 10% neutral-buffered formalin (Thermo Fisher, Waltham, MA) and left at 4 °C overnight followed by transfer into 70% ethanol and paraffin embedding to cut 5-μm sections. Distal colon sections (0.5–1 cm) were also collected and stored at −80 °C in cryogenic vials or RNAlater (Qiagen) to run western blots and RNA extraction, respectively.

Cell culture. CMT-93 cells obtained from ATCC were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 20 mM HEPES, 1% glutamine, penicillin (100 U ml−1) and streptomycin (100 μg ml−1; Sigma Chemicals Co., St. Louis, MD). Cells were maintained at 37 °C in a humidified incubator with 5% CO2. Cells grown to confluence were treated with recombinant RELM-β protein (100 ng ml−1) for 4 h or left untreated as controls.

Immunostaining. Tissue sections were deparaffinized by heating at 56 °C for 10 min, cleared with xylene, and rehydrated through an ethanol gradient to water. A phosphate-buffered saline containing 2% goat or donkey serum, 1% bovine serum albumin, 0.1% Triton X-100, 0.05% Tween20, and 0.05% sodium azide was used to block the sections. Primary antibodies specific for Muc2 (Santa Cruz Biotechnology, Dallas, TX), TFF3, RELM−β (Peprotech, Rocky Hill, NJ), Ly6g (BD Biosciences, Mississauga, Ontario, Canada), F4/80 (AbD Serotec, Raleigh, NC), CD3 (Abcam, Toronto, Ontario, Canada), E-cadherin (BD Biosciences), and REGIIIβ (R&D, Minneapolis, MN) were all diluted in the same phosphate-buffered saline buffer (1:200) and incubated with tissue sections for 60 min. Secondary antibodies included AlexaFluor 568-conjugated goat anti-rabbit immunoglobulin G, and AlexaFluor 568-conjugated goat anti-mouse (all obtained from Invitrogen (Burlington, Ontario, Canada) and used at 1:2000). Tissues were mounted using ProLong Gold Antifade reagent (Invitrogen) containing 4’,6’-diamidino-2-phenylindole for DNA staining. Sections were viewed using a Zeiss AxioImager microscope equipped with an AxioCam HRm camera (Munich, Germany).

Quantitative PCR analysis of cells, tissues, and stool samples. Total RNA from CMT-93 cells and colon tissues was extracted using the Qiagen RNeasy kit, as per manufacturer’s recommendations and 2 μg of RNA was used to generate complementary DNA using the Qiagen Omniscript RT kit. Colon contents were pre-weighed and DNA was extracted using the Stool DNA Mini Kit (Qiagen) according to their protocol. DNA was quantified using a NanoDrop Spectrophotometer (ND1000) and quantitative PCR was performed by adding 5 μl of either complementary DNA or stool DNA to 15 μl PCR reaction mix containing 10 μl SYBR green dye (Bio-Rad, Mississauga, Ontario, Canada) and 5 μl comprised of RNase/DNase-free water and primers to a final concentration of 0.6 μM. All reactions were assembled in duplicate and quantitative PCR carried out using a Bio-Rad Opticon2. Melting point analysis confirmed the specificity of the PCR. Results were quantified using GeneEx Macro OM 3.0 software (Bio-Rad) following the 2ΔΔCt method. For commensal analysis, the relative abundance was determined by calculating average Ct value normalized to each primer’s experimentally determined efficiency relative to the total 16S ribsosomal RNA bacteria (EUB). The specificity of Lactobacilli primers was further confirmed by ribsosomal RNA sequencing and blasting contig sequence in RDP program (East Lansing, MI). Primer sequences and reaction schemes are given in Table 1.

Table 1 Primer sets and PCR conditions

Crypt isolation and antimicrobial assays. Longitudinally opened colon tissues (0.5 cm) were incubated for 2 h at 4 °C in Cell Recovery solution (Corning, NY) and gently agitated to dislodge crypts. Approximately 2,000 isolated crypts were resuspended in 40 μl of iPIPES buffer (10 mM PIPES, 137 mM NaCl, pH 7.4) and incubated at 37 °C for 30 min followed by centrifugation at 1,500 r.p.m. for 10 min to collect supernatants. Overnight bacterial cultures were serially diluted and aliquoted to 1,000 bacteria per 100 μl per well into a 96-well plate. After centrifugation at 1,500 r.p.m. for 10 min, 10 μl of the appropriate crypt supernatant was added to the bacterial pellet and incubated for 2 h. Bacterial pellets incubated with only recombinant RegIIIβ protein (R&D), iPIPES buffer or water, were used as controls. The bacteria were then plated and incubated overnight at 37 °C and colony forming units counted.

Preparation of whole-tissue and crypt lysates. Crypts isolated as mentioned above were lysed on ice by pipetting up and down every 10 min for 30 min in RIPA buffer (150 mM NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 0.5% sodium deoxycholate, with 1% Triton X-100, 1% phosphatase inhibitor cocktail (Thermo Scientific, Burlington, Ontario, Canada) and protease inhibitor cocktail tablets (Roche, Mannheim, Germany)). Colon tissues (500 mg) were homogenized in 300 μl of RIPA buffer using a MixerMill for 5 min at 30 Hz for 2 h at 4 °C. Supernatants from tissue and crypt homogenates were collected following centrifugation at high speed (14,000 r.p.m. for 15 min at 4 °C). The proteins in the supernatants were analyzed using the Dc Protein Assay kit (Bio-Rad).

Preparation of stool lysates. One to two stool pellets were harvested and placed in 500 μl of U9 buffer (9 M Urea, 2%CHAPS, 50 mM Tris pH 9.0). Stool pellets were homogenized (as above) with a steel bead using a MixerMill and kept at room temperature for 1 h followed by mixing with 500 μl of U1 buffer (0.9 M Urea, 2% CHAPS, 50 mM Tris pH 9.0). Samples were then centrifuged at 14,000 r.p.m. for 10 min, and the supernatant was collected and quantified using a Dc Protein Assay kit.

Western blot analysis of crypts, whole-tissue lysates, and stool samples. Lysates prepared from crypts, whole tissues and stool samples were resolved by SDS–PAGE and transferred onto 0.2 μm polyvinylidene difluoride membranes (GE Healthcare, Buckinghamshire, UK). Membranes were blocked with 5% bovine serum albumin (Sigma, Oakville, Ontario, Canada) and probed using mouse anti-RELM-β, β-actin, or sheep anti-RegIIIβ (all at 1:2,000 dilution). Blots were incubated with horseradish peroxidase-conjugated anti-mouse or anti-sheep secondary antibodies (1:10,000 dilutions) and exposed to the SuperSignal West Dura substrate (Thermo). Proteins bands were visualized using a ChemiDocXRS system (Bio-Rad).

FISH staining. Stool pellets were weighed, diluted in phosphate-buffered saline and fixed overnight in 37% formalin. Samples were filtered through a 0.2 μm Whatman membrane and rehydrated using ethanol. For FISH hybridization, deparaffinized colon sections and membrane filters were incubated overnight in the dark at 37 °C with probes for either Lactobacilli AlexaFluor 488-conjugated (5′-IndexTermGTCCATTGTGGAAGATTCCC-3′) or total bacteria TexasRed-conjugated EUB (5′-IndexTermGCTGCCTCCCGTAGGAGT-3′), diluted to a final concentration of 2.5 ng μl−1 in hybridization buffer (0.9 M NaCl, 0.1 M Tris pH 7.2, 30% Formamide, 0.1% SDS). After washing in dark for 15 min in a wash buffer (0.9 M NaCl, 0.1 M Tris pH 7.2, 0.1% SDS), samples were air dried and mounted on slides using 4’,6’-diamidino-2-phenylindole and visualized with a Zeiss AxioImager microscope (GÎttingen, Germany). Stained bacteria were quantified as number of bacteria per gram of stool.

Histology and pathology scoring. Paraffin sections were deparaffinized and hematoxylin and eosin stained. Sections were mounted on microscope slides and visualized with a Zeiss AxioImager microscope. Histological scoring was based on previously adapted scoring systems.48, 49

Probiotic and antibiotic treatment in Muc2−/− mice. 12-week-old Muc2−/− mice were provided drinking water mixed with either 4 × 1010 Lactobacillus isolates 1 and 2 (1:1) previously isolated from mice and sequenced to confirm the species identity, or water mixed with 1.25 g l−1 of VSL#3 probiotic blend (VSL#3 Pharmaceuticals, North York, Ontario, Canada) containing a freeze dried blend of B. breve (DSM 24732), B. longum (DSM24736), B. infantis (SD5220DSM24737), L. acidophilus (DSM24735), L. plantarum (DSM24730), L. paracasei (DSM24733e), L. delbrueckii subsp Bulgaricus (DSM24733), and S. thermophiles (DSM24731) according to the manufacturer. Colon samples were harvested after 4 weeks of treatment and processed for analysis (as above). For antibiotic treatment, 12-week-old Muc2−/− mice were treated per-orally with 200 μl of antibiotics (1 g l−1 ampicillin sodium, 0.5 l−1 vancomycin hydrochloride, 1 g l−1 neomycin sulfate and 1 g l−1 metronidazole) once a day for a period of 8 days and compared with untreated controls.

SCFA analysis. Using gas chromatography, the amount of acetic, propionic, and butyric acid was analyzed from colon samples as previously described.50 Briefly, colon samples were scraped into a fecal slurry and homogenized in isopropyl alcohol containing 2-ethylbutyric acid at 0.01% v/v. The homogenate was centrifuged and the supernatant injected into a fused-silica FAMEWAX column (Restek Cat#12498, Bellefonte, PA) on a trace 1,300 Gas Chromatograph equipped with flame-ionization detector and AI1310 autosampler (Thermo Scientific) in splitless mode. Peaks were analyzed on Chromeleon 7 Software (Sunnyvale, CA) and the areas under peaks for acetic, propionic, and butyric acid were represented as percent weight of total sample. Samples were normalized by measuring SCFAs in 50 mg of colonic tissue content using 1 ml of isopropyl alcohol solvent per sample.

Statistics. Results were expressed as means±s.e.m. of separate experiments. Graph Pad Prism 4 statistical software (GraphPad Software, San Diego, CA) was used to perform data analysis. Differences between means were calculated by Student’s t-tests, χ2-test or analysis of variance (one-way, two-way or multiple) where appropriate. Specific differences were tested with Bonferroni’s or post hoc Tukey test when comparing more than two groups. P<0.05 was considered statistically significant.

References

  1. 1

    Sartor, R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 390–407 (2006).

  2. 2

    Matricon, J., Barnich, N. & Ardid, D. Immunopathogenesis of inflammatory bowel disease. Self Nonself 1, 299–309 (2010).

  3. 3

    Comito, D. & Romano, C. Dysbiosis in the pathogenesis of pediatric inflammatory bowel diseases. Int. J. Inflamm. 2012, 687143 (2012).

  4. 4

    Johansson, M.E., Larsson, J.M. & Hansson, G.C. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc. Natl Acad. Sci. USA 108 (Suppl 1), 4659–4665 (2011).

  5. 5

    Deplancke, B. & Gaskins, H.R. Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. Am. J. Clin. Nutr. 73, 1131S–1141S (2001).

  6. 6

    Hansson, G.C. & Johansson, M.E. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Gut Microbes 1, 51–54 (2010).

  7. 7

    Fyderek, K. et al. Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. World J. Gastroenterol. 15, 5287–5294 (2009).

  8. 8

    Schwerbrock, N.M. et al. Interleukin 10-deficient mice exhibit defective colonic Muc2 synthesis before and after induction of colitis by commensal bacteria. Inflamm. Bowel Dis. 10, 811–823 (2004).

  9. 9

    Johansson, M.E.V. et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 63, 281–291 (2013).

  10. 10

    Johansson, M.E. et al. Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PLoS ONE 5, e12238 (2010).

  11. 11

    Van der Sluis, M. et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131, 117–129 (2006).

  12. 12

    Velcich, A. et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295, 1726–1729 (2002).

  13. 13

    Artis, D. et al. RELMbeta/FIZZ2 is a goblet cell-specific immune-effector molecule in the gastrointestinal tract. Proc. Natl Acad. Sci. USA 101, 13596–13600 (2004).

  14. 14

    Herbert, D.R. et al. Intestinal epithelial cell secretion of RELM-beta protects against gastrointestinal worm infection. J. Exp. Med. 206, 2947–2957 (2009).

  15. 15

    Steppan, C.M. et al. A family of tissue-specific resistin-like molecules. Proc. Natl Acad. Sci. USA 98, 502–506 (2001).

  16. 16

    Krimi, R.B. et al. Resistin-like molecule beta regulates intestinal mucous secretion and curtails TNBS-induced colitis in mice. Inflamm. Bowel Dis. 14, 931–941 (2008).

  17. 17

    He, W. et al. Bacterial colonization leads to the colonic secretion of RELMbeta/FIZZ2, a novel goblet cell-specific protein. Gastroenterology 125, 1388–1397 (2003).

  18. 18

    Mishra, A. et al. Resistin-like molecule-beta is an allergen-induced cytokine with inflammatory and remodeling activity in the murine lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L305–L313 (2007).

  19. 19

    Barnes, S.L. et al. Resistin-like molecule beta (RELMbeta/FIZZ2) is highly expressed in the ileum of SAMP1/YitFc mice and is associated with initiation of ileitis. J. Immunol. 179, 7012–7020 (2007).

  20. 20

    Bergstrom, K.S. et al. Goblet cell derived RELM-beta recruits CD4+ T cells during infectious colitis to promote protective intestinal epithelial cell proliferation. PLoS Pathog. 11, e1005108 (2015).

  21. 21

    McVay, L.D. et al. Absence of bacterially induced RELMbeta reduces injury in the dextran sodium sulfate model of colitis. J. Clin. Invest. 116, 2914–2923 (2006).

  22. 22

    Hogan, S.P. et al. Resistin-like molecule beta regulates innate colonic function: barrier integrity and inflammation susceptibility. J. Allergy Clin. Immunol. 118, 257–268 (2006).

  23. 23

    Burger-van Paassen, N. et al. Mucin Muc2 deficiency and weaning influences the expression of the innate defense genes Reg3beta, Reg3gamma and angiogenin-4. PLoS ONE 7, e38798 (2012).

  24. 24

    Huang, E.Y. et al. Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflamm. Bowel Dis. 21, 963–972 (2015).

  25. 25

    Vinolo, M.A., Rodrigues, H.G., Nachbar, R.T. & Curi, R. Regulation of inflammation by short chain fatty acids. Nutrients 3, 858–876 (2011).

  26. 26

    Specian, R.D. & Oliver, M.G. Functional biology of intestinal goblet cells. Am. J. Physiol. 260 (2 Pt 1), C183–C193 (1991).

  27. 27

    Banerjee, R.R. et al. Regulation of fasted blood glucose by resistin. Science 303, 1195–1198 (2004).

  28. 28

    Nair, M.G., Guild, K.J. & Artis, D. Novel effector molecules in type 2 inflammation: lessons drawn from helminth infection and allergy. J. Immunol. 177, 1393–1399 (2006).

  29. 29

    Karmiris, K., Koutroubakis, I.E., Xidakis, C., Polychronaki, M., Voudouri, T. & Kouroumalis, E.A. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm. Bowel Dis. 12, 100–105 (2006).

  30. 30

    Konrad, A. et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur. J. Gastroenterol. Hepatol. 19, 1070–1074 (2007).

  31. 31

    Bhinder, G. et al. Intestinal epithelium-specific MyD88 signaling impacts host susceptibility to infectious colitis by promoting protective goblet cell and antimicrobial responses. Infect. Immun. 82, 3753–3763 (2014).

  32. 32

    Wolk, K., Kunz, S., Witte, E., Friedrich, M., Asadullah, K. & Sabat, R. IL-22 increases the innate immunity of tissues. Immunity 21, 241–254 (2004).

  33. 33

    Rendon, J.L., Li, X., Akhtar, S. & Choudhry, M.A. Interleukin-22 modulates gut epithelial and immune barrier functions following acute alcohol exposure and burn injury. Shock 39, 11–18 (2013).

  34. 34

    Johansson, M.E., Thomsson, K.A. & Hansson, G.C. Proteomic analyses of the two mucus layers of the colon barrier reveal that their main component, the Muc2 mucin, is strongly bound to the Fcgbp protein. J. Proteome Res. 8, 3549–3557 (2009).

  35. 35

    Vaishnava, S. et al. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science 334, 255–258 (2011).

  36. 36

    Miki, T., Holst, O. & Hardt, W.D. The bactericidal activity of the C-type lectin RegIIIbeta against Gram-negative bacteria involves binding to lipid A. J. Biol. Chem. 287, 34844–34855 (2012).

  37. 37

    Mukherjee, S. et al. Antibacterial membrane attack by a pore-forming intestinal C-type lectin. Nature 505, 103–107 (2014).

  38. 38

    Zocco, M.A. et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 23, 1567–1574 (2006).

  39. 39

    Madsen, K.L., Doyle, J.S., Jewell, L.D., Tavernini, M.M. & Fedorak, R.N. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116, 1107–1114 (1999).

  40. 40

    Louis, P. & Flint, H.J. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol. Lett. 294, 1–8 (2009).

  41. 41

    Tedelind, S., Westberg, F., Kjerrulf, M. & Vidal, A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J. Gastroenterol. 13, 2826–2832 (2007).

  42. 42

    Anderson, J.W. & Bridges, S.R. Short-chain fatty acid fermentation products of plant fiber affect glucose metabolism of isolated rat hepatocytes. Proc. Soc. Exp. Biol. Med. 177, 372–376 (1984).

  43. 43

    Mizoguchi, A. Healing of intestinal inflammation by IL-22. Inflamm. Bowel Dis. 18, 1777–1784 (2012).

  44. 44

    Pickert, G. et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206, 1465–1472 (2009).

  45. 45

    Barshishat, M., Polak-Charcon, S. & Schwartz, B. Butyrate regulates E-cadherin transcription, isoform expression and intracellular position in colon cancer cells. Br. J. Cancer 82, 195–203 (2000).

  46. 46

    Casas, I.A. & Dobrogosz, W.J. Validation of the probiotic concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals. Microb. Ecol. Health Dis. 12, 247–285 (2000).

  47. 47

    Hogan, S. et al. Resistin-like molecule beta regulates innate colonic function: barrier integrity and inflammation susceptibility. J. Allergy Clin. Immunol. 118, 257–268 (2006).

  48. 48

    Bergstrom, K.S. et al. Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog. 6, e1000902 (2010).

  49. 49

    Sham, H.P. et al. SIGIRR, a negative regulator of TLR/IL-1R signalling promotes Microbiota dependent resistance to colonization by enteric bacterial pathogens. PLoS Pathog. 9, e1003539 (2013).

  50. 50

    Brown, K. et al. Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice. ISME J advance online publication, 14 August 2015; doi:10.1038/ismej.2015.114 (2015).

Download references

Acknowledgements

We would like to thank Dr Karen Madsen for providing the Lactobacilli isolates used in this study, Dr Sanjoy Ghosh for providing gas chromatography equipment to analyze SCFA and Dr Meera Nair for helpful discussions. Operating grants to B.A.V. from the Canadian Institutes for Health Research (CIHR) and Crohn’s and Colitis Canada (CCC).

Author information

Correspondence to B A Vallance.

Ethics declarations

Competing interests

The authors declared no conflict of interest.

Additional information

Author contributions

V.M., K.S.B, and B.A.V. conceived and designed the experiments. V.M., U.D., G.B., C.M., and T.H. performed the experiments.V.M. and U.D. analyzed the data: D.L.G. provided reagents, V.M., U.D., K.J., D.L.G., and B.A.V. wrote the paper.

SUPPLEMENTARY MATERIAL is linked to the online version of the paper

Supplementary information

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Morampudi, V., Dalwadi, U., Bhinder, G. et al. The goblet cell-derived mediator RELM-β drives spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis. Mucosal Immunol 9, 1218–1233 (2016) doi:10.1038/mi.2015.140

Download citation

Further reading